Overview
Spirair develops minimally invasive ENT medical devices. Its SeptAlign system uses a bioabsorbable implant to straighten minor nasal septal deviations in an in-office procedure under local anesthesia, with the implant dissolving in about six months after the cartilage holds its new shape. In 2025 it added TurbAlign to separate the middle turbinate from the nasal wall to aid healing after sinus surgery. The company sells these devices to ENT professionals and differentiates itself by tissue-preserving implants for office-based correction, aiming to improve nasal airway outcomes with less invasive options and shorter recovery.
Work here?Claim your company
About Spirair
Industries
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Mountain View, California
Founded
2020
Get referred to Spirair
See people who can refer or advise you
Simplify's Take
What believers are saying
- Spirair secured two FDA clearances within seven months, broadening its ENT device portfolio.
- The company updated news through August 2026, indicating active commercial and regulatory momentum.
- Local-anesthesia office procedures attract ENTs seeking faster throughput than operating-room septoplasty.
What critics are saying
- Cigna's 2026 policy excludes absorbable nasal implants, crushing reimbursement for Spirair sales.
- Septoplasty remains broadly covered in 2026, keeping cheap surgical incumbents entrenched.
- Spirair filed a 2025 exempt offering for $23.6 million, signaling continuing capital dependence.
What makes Spirair unique
- SeptAlign won FDA clearance on January 16, 2026 for nasal septal deviation.
- TurbAlign won FDA clearance on July 11, 2025 for post-sinus-surgery healing support.
- Stanford Biodesign founders Brandon McCutcheon and James Kintzing built a surgeon-led ENT platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Growth & Insights and Company News
6 month growth
20%1 year growth
20%2 year growth
26%Spirair has filed a notice with the U.S. SEC for an exempt offering of securities to raise up to $23.6 million in new funding. This filing is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, using exemptions like Rule 504 or 506 of Regulation D. The notice must be filed within 15 days of the first sale. Spirair specializes in minimally invasive solutions for ENT care.
Spirair is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Spirair
Industries
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Mountain View, California
Founded
2020
Spirair is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today